Holen Sie sich die Stockscreener-App
1.61
1.90%
0.03
Schlusskurs vom Vortag:
$1.58
Offen:
$1.6
24-Stunden-Volumen:
38,893
Relative Volume:
0.10
Marktkapitalisierung:
$125.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-46.12M
KGV:
-1.863
EPS:
-0.8642
Netto-Cashflow:
$-41.02M
1W Leistung:
-6.94%
1M Leistung:
+73.32%
6M Leistung:
+3.21%
1J Leistung:
+34.17%
1-Tages-Spanne:
$1.60
$1.705
1-Wochen-Bereich:
$1.42
$1.85
52-Wochen-Spanne:
$0.8238
$2.815
Inflarx N V Stock (IFRX) Company Profile
Vergleichen Sie IFRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
1.61 | 125.33M | 0 | -46.12M | -41.02M | -0.8642 |
|
VRTX
Vertex Pharmaceuticals Inc
|
431.22 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
538.75 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
548.76 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.18 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.21 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-02-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-10-28 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-06 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-04-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-05 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-06-05 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | Herabstufung | SunTrust | Buy → Hold |
| 2019-01-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-10 | Eingeleitet | Credit Suisse | Outperform |
| 2018-07-13 | Eingeleitet | BMO Capital Markets | Outperform |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-28 | Eingeleitet | SunTrust | Buy |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Inflarx N V Aktie (IFRX) Neueste Nachrichten
Oppenheimer Initiates Coverage of InflaRx N.V. (IFRX) with Outperform Recommendation - Nasdaq
This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday - Benzinga
InflaRx N.V. Reports Q1 2025 Financial Results - TipRanks
InflaRx reports Q1 EPS (EUR 0.13) vs (EUR 0.17) last year - TipRanks
InflaRx Reports Q1 2025 Financial Results with Reduced Losses - TipRanks
InflaRx (IFRX) Awaits Key Milestones in Drug Development | IFRX Stock News - GuruFocus
InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
InflaRx NV expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Grows Stake in InflaRx (NASDAQ:IFRX) - Defense World
InflaRx To Reveal Next Month Its Late-Stage Interim Results Of Lead Drug In Painful Ulcer - RTTNews
InflaRx (NASDAQ:IFRX) Earns Overweight Rating from Analysts at Cantor Fitzgerald - Defense World
Cantor Fitzgerald Predicts InflaRx FY2025 Earnings - Defense World
InflaRx (IFRX) Projected to Post Quarterly Earnings on Wednesday - Defense World
What is InflaRx N.V (IFRX) Stock Return on Shareholders’ Capital? - Sete News
Checking in on InflaRx N.V (IFRX) after recent insiders movement - knoxdaily.com
InflaRx N.V (IFRX) Stock: The Story of a 52-Week Stock Range - investchronicle.com
InflaRx N.V (IFRX) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
InflaRx to Report First Quarter 2025 Results on May 7, 2025 - GlobeNewswire
InflaRx, Pioneer in Anti-Inflammatory Therapeutics, Announces Q1 2025 Earnings Date - Stock Titan
Cantor Fitzgerald Initiates Coverage of InflaRx N.V. (IFRX) with Overweight Recommendation - MSN
Cantor Fitzgerald sets $10 target for Inflarx stock, cites catalysts By Investing.com - Investing.com South Africa
Biotech Shares Jump As Institutional Coverage Begins With Positive Outlook - The Globe and Mail
Cantor Fitzgerald sets $10 target for Inflarx stock, cites catalysts - Investing.com
Cantor Fitzgerald Initiates InflaRx at Overweight $10 Price Target - marketscreener.com
InflaRx (IFRX) Projected to Rise with Upcoming Phase 3 Data Rele - GuruFocus
InflaRx Approves Key Resolutions at Annual Shareholder Meeting - MSN
InflaRx launches public offering of shares and warrants - MSN
Commonwealth Equity Services LLC Has $275,000 Stock Holdings in InflaRx (NASDAQ:IFRX) - Defense World
InflaRx N.V. Announces 2025 Annual General Meeting Agenda - TipRanks
Raymond James Financial Inc. Purchases Shares of 638,092 InflaRx (NASDAQ:IFRX) - Defense World
Guggenheim Forecasts Strong Price Appreciation for InflaRx (NASDAQ:IFRX) Stock - Defense World
Guggenheim raises Inflarx stock target to $10, maintains Buy rating By Investing.com - Investing.com Australia
InflaRx price target raised to $10 from $7 at Guggenheim - TipRanks
InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Guggenheim raises Inflarx stock target to $10, maintains Buy rating - Investing.com India
HC Wainwright Reiterates “Buy” Rating for InflaRx (NASDAQ:IFRX) - Defense World
InflaRx N.V. Reports 2024 Results and Key Achievements - TipRanks
InflaRx NV reports results for the quarter ended December 31Earnings Summary - TradingView
InflaRx stock reiterated at Buy at H.C. Wainwright after EU drug approval - MSN
InflaRx reports Q EPS (EUR 0.78) vs (EUR 0.78) last year - TipRanks
InflaRx Reports 2024 Results and Outlines 2025 Milestones - TipRanks
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones - GlobeNewswire
InflaRx 2024 Earnings Reveal Strong Cash Position and Major EU Drug Win - StockTitan
Short Interest in InflaRx (NASDAQ:IFRX) Grows By 46.2% - Defense World
InflaRx (IFRX) Projected to Post Earnings on Thursday - Defense World
InflaRX Presents Efficacy and Safety Data on Vilobelimab at AAD 2025 - Dermatology Times
InflaRx (NASDAQ:IFRX) Earns Buy Rating from HC Wainwright - Defense World
InflaRx announces presentation of multiple posters on utility of vilobelimab - TipRanks
InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting - GlobeNewswire
Can This Drug Transform Hidradenitis Suppurativa Treatment? New Data Shows 3x Better Results - StockTitan
InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting - GlobeNewswire
Finanzdaten der Inflarx N V-Aktie (IFRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.11%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):